Physicians' Academy for Cardiovascular Education

Initiation of SGLT2i in CKD: how, when and who?

10' education - June 27, 2023 - David Cherney, MD, PhD (Toronto, ON, Canada), Roberto Pecoits-Filho, MD, PhD (Curitiba, Brazil/ Ann Arbor, MI, USA), and Magdalena Madero, MD (Mexico City, Mexico)

Video navigation menu

  • How to identify patients who are elibible for treatment with SGLT2i 00:04
  • When to start therapy with SGLT2i 02:54
  • Who should prescribe SGLT2i? 04:56
  • Take home messages 08:28

In which patients with CKD would you start SGLT2i therapy?

  • A. Only in patients who also have diabetes
  • B. Only in patients who also have diabetes or heart failure
  • C. In patients with albuminuria >200 mg/g, or heart failure, or diabetes

Educational information

David Cherney, MD, PhD, Roberto Pecoits-Filho, MD, PhD, and Magdalena Madero, MD were discussants at the EBAC-accredited symposium "Sharing international experience in CKD & SGLT2i: How to identify the right patient at the right moment?" held during the WCN 2023 in Bangkok, Thailand.



This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.


Funding for this educational program was provided by an unrestricted educational grant received from Boehringer Ingelheim and Lilly Alliance.

Watch other videos in this series

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: